$REPL

Schwendenman Andrew sold $99K of REPL

Schwendenman Andrew (Chief Accounting Officer) sold 7,632 shares of Replimune Group, Inc. (REPL) at $12.97 on 2026-08-10.

Original reporting
SEC EDGAR · Schwendenman Andrew
Published Aug 12, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value, and post-transaction holdings). No operational or financial updates are provided.

02

Market read

Traders may note the insider sale as a small sentiment datapoint, but there is no fundamental catalyst in the filing.

03

What to watch

Insider sales can be scheduled around personal events and do not reflect forward-looking valuation unless paired with other disclosures (guidance changes, financing, litigation, or clinical/regulatory milestones).

Relevance 3/10Novelty 3/10Timing: filed Aug. 12, transaction dated Aug. 10

Background

The article is an SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune Group disclosed an insider open-market sale by CFO Andrew Schwendenman of 7,632 shares at $12.97 on Aug. 10.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include new company performance, guidance, or regulatory/contract developments. The disclosed sale size is also relatively small versus typical market-moving thresholds.

Market effects

Minimal. Insider-sale Form 4s rarely reset sector expectations without accompanying company-specific news.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply bearish intent; insiders may sell for diversification, taxes, or planned personal liquidity needs.

Key entities

  • Replimune Group, Inc.

    Company whose insider transaction was disclosed on Form 4.

  • Schwendenman Andrew

    Chief Accounting Officer who sold 7,632 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

New FDA Drug Approvals - August 2026

The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.

$REPLHighAI 8/10

REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome

Replimune Group (REPL) stock surged 140% in pre-market trading after a favorable FDA advisory committee review of its melanoma therapy RP1. Cantor Fitzgerald upgraded REPL to 'Overweight' from 'Neutral', citing an 'overwhelmingly positive' panel outcome. The FDA is expected to make a final decision by Aug. 2, 2026. REPL's stock has fallen 39% year-to-date.

$REPLHighAI 8/10

Replimune Group stock hits 52-week high at 16.2 USD

Replimune Group Inc (REPL) hit a 52-week high of $16.20, up 165.99% over the past year. Analysts have mixed views, with price targets ranging from $14 to $24. The FDA's approval of its cancer treatment, TUDRIQEV, has drawn positive attention from analysts, with upgrades and increased price targets. The company's earnings report is anticipated to impact stock movement.

$REPLLowAI 8/10

Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process - TipRanks.com

Replimune Group (NASDAQ: REPL) and its leaders filed a motion to dismiss a lawsuit alleging securities violations over statements about its melanoma treatment RP1's FDA approval process. The investors claim Replimune misled them about FDA feedback on the IGNYTE trial. Replimune argues it disclosed risks and that the FDA ultimately approved RP1 in August 2026.